Phaseline

Companies › ImmuneSensor Therapeutics

ImmuneSensor Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 11 registered trials: 4 Phase 2, 3 Phase 1, 3 Phase 3, 1 Phase 4; Oncology, Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IMSA101
Intra-tumoral immunotherapy agent
–Phase 1Solid Tumor, Adult; Metastatic Renal Cell Carcinoma ( mRCC)–
IMSB301
Unclear - mechanism not specified in registry text
–Phase 1Type 1 Interferonopathies–
Immune Checkpoint Inhibitor (ICI)
Immune checkpoint inhibition
–Phase 1Solid Tumor, Adult; Advanced Biliary Tract Carcinoma; Non-Small Cell Lung Cancer; TNBC - Triple-Negative Breast Cancer …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06026254IMSA101Phase 1Solid Tumor, AdultOncologySep 2025
NCT06026254Immune Checkpoint Inhibitor (ICI)Phase 1Solid Tumor, AdultOncologySep 2025
NCT07364513IMSB301Phase 1Type 1 InterferonopathiesImmunologyJul 2026
NCT05522660Immune Checkpoint Inhibitor (ICI)Phase 3Non-Small Cell Lung CancerOncologyDec 2026
NCT07572864Immune Checkpoint Inhibitor (ICI)Phase 2Head and Neck Squamous Cell CarcinomaOncologyMay 2027
NCT06601296IMSA101Phase 2Metastatic Renal Cell Carcinoma ( mRCC)OncologyOct 2027
NCT07759856Immune Checkpoint Inhibitor (ICI)Phase 2Small Cell Lung CancerOncologyAug 2028
NCT06154538Immune Checkpoint Inhibitor (ICI)Phase 2Locally Advanced Colorectal CarcinomaOncologyNov 2028
NCT07405086Immune Checkpoint Inhibitor (ICI)Phase 4Advanced Biliary Tract CarcinomaOncologyDec 2028
NCT06627712Immune Checkpoint Inhibitor (ICI)Phase 3TNBC - Triple-Negative Breast CancerOncologyNov 2029
NCT07590024Immune Checkpoint Inhibitor (ICI)Phase 3Nasopharyngeal Carcinoma (NPC)OncologyDec 2030

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.